MedTrace Logo

Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00004896 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of busulfan and cyclophosphamide followed by bone marrow transplantation in treating patients who have acute myelogenous leukemia or myelodysplastic syndrome.

Conditions

Interventions

DRUG

busulfan

DRUG

cyclophosphamide

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

bone marrow ablation with stem cell support

RADIATION

radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Martin S. Tallman, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2004-08-31
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004896 on ClinicalTrials.gov